Ozempic (semaglutide) cuts dementia risk compared with Januvia (sitagliptin): Oxford study.-Novo Nordisk
Trials have already shown that Novo Nordisk’s semaglutide can cut the risk of cardiovascular events and kidney disease. Now a study from the University of Oxford indicates that the company’s semaglutide type 2 diabetes drug Ozempic can reduce the risk of dementia compared with another popular diabetes medicine.
The research—which was designed to demonstrate if Ozempic could cause neurologic problems—showed instead that it produced a 48% decline in dementia when compared to Merck’s type 2 diabetes drug Januvia (sitagliptin) . The Oxford study also showed that Ozempic provided a 28% reduction in “nicotine misuse” when compared to Januvia and Pfizer’s older type 2 diabetes drug Glucotrol (glipizide).
Novo Nordisk is conducting two phase III studies—EVOKE and EVOKE+—investigating semaglutide in 1,800 patients with early Alzheimer’s disease. Novo expects results from the studies to read out in 2026.
See- "12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study"- Riccardo De Giorgi, Ivan Koychev, Amanda I. Adler, Philip J. Cowen, Catherine J. Harmer, Paul J. Harrison, and Maxime Taquet -.eClinicalMedicine 2024;: 102726. Published Online xxx https://doi.org/10. 1016/j.eclinm.2024. 102726.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins